Eli Lilly's stock has surged 598.87% since early 2020, indicating a strong market performance with potential for future growth as it expands in key therapeutic areas.
Investors are focusing on Eli Lilly's projected revenue and net income for the next 3 to 5 years, as the company considers its strategic expansions and ongoing innovations.
The company plans to invest $1.8 billion to expand production for its obesity and Alzheimer's drugs in Ireland, reflecting its commitment to meeting high demand.
Despite some side effects like nausea, recent studies show Eli Lilly's obesity drugs are effective, particularly in women, reinforcing trust in its product development.
Collection
[
|
...
]